Navigation Links
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Date:11/24/2009

SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.

The stock option is intended to be an incentive stock option to the extent permitted by law and has an exercise price per share equal to $7.52, the fair market value on the grant date. The stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to Dr. Klassen's continued service relationship with the Company on each such date. This stock option has a ten year term and is subject to the terms and conditions of the Company's 2007 Equity Incentive Award Plan and the stock option agreement pursuant to which the option is granted.

The stock option was granted as an inducement material to Dr. Klassen's entering into employment with Orexigen Therapeutics in accordance with NASDAQ listing Rule 5635(c)(4).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... The Eastern European medical device industry is ... well as new medical-device manufacturers are constantly trying to ... ways to reduce the cost incurred for placing their ... the effective means to achieve this target. This research ... European and provides profiles of key distributors in ...
(Date:9/30/2014)... Sept. 30, 2014 Passport Health, one of ... , has launched FluFree.com, a website designed to promote, ... For 20 years, Passport Health has provided its ... The launch of FluFree.com is designed to address the ... number of people who actually chose to get vaccinated. ...
(Date:9/30/2014)... MUNSTER, Ind. , Sept. 30, 2014  The orthopedic ... ranked the nation,s No. 6 orthopedic group by US ... for Active Adults," a series of free, public seminars ... from all over the world come to see the ... replacement procedures are now available at Munster Specialty Surgery ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2
... Feb. 27, 2012  GP Strategies Corporation (NYSE: ... provider of sales and technical training, e-Learning solutions, management ... Greenberg and CFO Sharon Esposito-Mayer will speak at the ... 2012, at 10:55 a.m. ET. The conference will be ...
... 27, 2012 Nektar Therapeutics (Nasdaq: NKTR ) ... its new oral opioid analgesic molecule, at the 2012 American ... a novel mu-opioid agonist molecule, which was designed to have ... the attractiveness of the molecule as a target of abuse ...
Cached Medicine Technology:Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 2Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 3Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 4Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 5Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 6Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 7Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 8Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 9Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting 10
(Date:10/1/2014)... October 01, 2014 The Oliver ... a new Other-Sonic Ultrasound Gel lawsuit web ... about the litigation surrounding the 2011 Pseudomonas aeruginosa ... in Royal Oak, Michigan, which was ultimately traced ... is representing William Beaumont patients who allegedly became ...
(Date:10/1/2014)... MI (PRWEB) October 01, 2014 To help ... wellness center , Cutler Integrative Medicine, is detailing several tips ... , According to Dr. Cutler, women should start ... quality time for yourself that will help ‘center’ yourself for ... of stress,” he says. , Other health and fitness ...
(Date:9/30/2014)... third of medical and nursing students in developing countries ... countries after graduation, while less than one fifth of ... are needed most, according to a new study. , ... the current outbreak of Ebola in western Africa. The ... of the world,s poorest countries (Guinea, Sierra Leone and ...
(Date:9/30/2014)... carbon emissions will reduce other harmful air pollution ... a new study released today. The research shows ... the final Clean Power Plan, the power plant ... hospitalizations, and hundreds of heart attacks in the ... Health Co-benefits of Carbon Standards for Existing Power ...
(Date:9/30/2014)... stranger to the children of Tanzania. What is rare ... services, including reliable diagnosis and evidence-based treatments. There is ... in Swahili, a major language of the region. In ... and the University of Georgia (UGA) describe a culturally ... in the country and found to be effective for ...
Breaking Medicine News(10 mins):Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Developing countries should enroll medical and nursing students from rural areas 2Health News:Developing countries should enroll medical and nursing students from rural areas 3Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4
... There is an increasing number of HIV cases reported among ... by the Centre for disease control and prevention (CDC) and ... sharing and using the same needle up to 15 times ... ,The researchers are very worried and discussed about ...
... have found that a protein known for driving the ... restoring the ability of neurons to regenerate // , ... damage or neurological diseases like Alzheimers., ,"The finding ... proliferating cancer could also potentially be used to regrow ...
... help people lose weight, will be launched in the UK.This ... that controls //the desire to over-eat and it has been ... worldwide to have access to the medication. ,It ... loss by blocking the brain's craving signals, thereby suppressing the ...
... vaccination experts have written an open letter in the Scotsman ... the rumors// that MMR Vaccine was linked to autism. ... taken, the UK could face a serious situation with outbreaks ... questions of "any association between MMR and autism" should be ...
... contraceptive pill intended for consumption without a break is ... The pill, named Anya, manufactured by Wyeth Pharmaceuticals, is ... to give a merry slip to the monthly period! ... is undergoing a testing period marked by extensive clinical ...
... of transplant surgeries, doctors are rethinking on the guidelines ... (AHEC) is deliberating //over the permission for medical procedures ... on the ventilator, with a motive to remove organs ... the issue of removal of organs from the patient ...
Cached Medicine News:Health News:Wonder Drug For Weight Loss Launched In UK 2
Portable shields for your safety and convenience....
Provide 1.5mm protection throughout. Six durable, attractive vinyl coverings are available. Lead glass window factory installed. Larger window available....
Swing-Arm™ Scatter Shield® provides lower extremity protection for personnel close to the tube. 24"Wx32"L lead shield swings 180 along table. Ideal for cardiac cath, special studies, electr...
Front Protection with attached Belt Guard, Built-in Back Support; Buckle Closure...
Medicine Products: